...
机译:晚期实体瘤患者每日两次(BID)口服PI3K / mTOR双重抑制剂BEZ235香囊制剂的1期研究
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
">(4);
Sarah Cannon Research Institute">(1);
Stephenson Cancer Center">(3);
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
Sarah Cannon Research Institute">(1);
Tennessee Oncology PLLC">(2);
Sarah Cannon Research Institute">(1);
Sarah Cannon Research Institute">(1);
Sarah Cannon Research Institute">(1);
BEZ235; PI3K/mTOR; Sachet formulation; Dose escalation;
机译:晚期实体瘤患者每天两次口服(BID)口服PI3K / mTOR双重抑制剂BEZ235香囊制剂的1期研究
机译:在患有先进乳腺癌的患者的患者中,BEZ235,双PI3K / MTOR抑制剂的BEZ235,双PI3K / MTOR抑制剂的升级和膨胀研究
机译:先进实体肿瘤患者口服双PI3K和MTORC1 / 2抑制剂PQR309的首先人,第1期,剂量 - 升级药代动力学和药效学研究(SAKK 67/13)
机译:内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
机译:BEZ235,PI3K / mTOR抑制剂和依维莫司,mTOR抑制剂的新型组合的临床药代动力学:I期临床研究和非临床机制评估
机译:BEZ235(PI3K / mTOR双重抑制剂)在晚期实体瘤患者(包括晚期乳腺癌)中的1 / 1b剂量递增和扩展研究
机译:晚期实体恶性肿瘤患者双重PI3K / mTOR抑制剂Dactolisib(BEZ235)联合依维莫司的Ib期研究